Inotek Pharmaceuticals Corporat shares had a trading volume of 426K on Tuesday. Volume was down 80.94% under the stocks average daily volume.
Traders are more bullish on Inotek Pharmaceuticals Corporat recently if you watch the fall in short interest. The firm recorded a fall in short interest of -6.93% as of the latest report on October 13, 2017. Short interest fell from 2,643,362 to 2,460,245 over that period. Days to cover decreased from 2.0 to 1.0 and the short interest percentage is 0.13% as of October 13.
The following firms have recently changed their position in ITEK. As of the end of the quarter Ft Options LLC had sold 446,463 shares trimming its position 93.4%. The value of the investment in Inotek Pharmaceuticals Corporat decreased from $956,000 to $39,000 decreasing 95.9% quarter to quarter. As of quarter end Cutler Group LP had acquired a total of 500 shares growing its holdings by 125.0%. The value of the company’s investment in Inotek Pharmaceuticals Corporat went from $0 to $0 a change of nan% quarter over quarter.
Meeder Asset Management Inc augmented its investment by buying 2,431 shares an increase of 384.0%. Meeder Asset Management Inc claims 3,064 shares with a value of $5,000. The value of the position overall is up by 400.0%. Simplex Trading, LLC grew its holdings by buying 898 shares an increase of 19.8% as of 09/30/2017. Simplex Trading, LLC now holds 5,440 shares worth $9,000. The total value of its holdings increased 12.5%.
The company is so far trading down by 2.33% since yesterday’s close of $2.52. Company shares last traded at $2.52 which is significantly higher than the 50 day moving average of $2.09 and which is impressively higher than the 200 day moving average of $1.63. The 50 day moving average was up $0.43 and the 200 day average moved up $0.89.
Inotek Pharmaceuticals Corporation, launched on July 7, 1999, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM)..